Loading institutional data...
Loading institutional data...
Insufficient data to determine institutional momentum.
Data as of Q2 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Ranked against 17 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-06-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SGHT | $467M | — | — | 6.0× | -3.1% | 86.2% | -49.7% | -60.1% | -36.9% | — | 115 |
| NPCE | $438M | — | — | 4.4× | 25.1% | 77.2% | -21.5% | -113% | -27.5% | — | 110 |
| CARL | $393M | — | — | 7.8× | 85.9% | 75.3% | -58.7% | -30.0% | -25.9% | — | 74 |
| SI | $390M | — | — | 8.2× | 49.6% | 76.5% | -85.3% | -28.7% | -25.9% | — | 73 |
| OFIX | $375M | — | — | 0.5× | 2.9% | 68.8% | -11.2% | -20.5% | -15.2% | — | 142 |
| EMBC | $335M | 3.6× | 5.3× | 0.3× | -3.8% | 62.6% | 8.8% | -14.7% | 12.8% | 4.2× | 318 |
| CLPT | $325M | — | — | 8.8× | 17.8% | 61.4% | -69.1% | -91.1% | -33.1% | — | 130 |
| INFU | $265M | 43.0× | 11.6× | 1.9× | 6.4% | 56.0% | 4.6% | 11.6% | 8.6% | 0.7× | 98 |
| ANIK | $261M | — | — | 2.3× | -5.9% | 56.6% | -9.6% | -7.6% | -7.6% | — | 131 |
| OSUR | $257M | — | — | 2.2× | -38.1% | 41.9% | -59.8% | -20.2% | -20.2% | — | 150 |
| TMCI | $253M | — | — | 1.2× | 1.6% | 79.8% | -27.7% | -67.6% | -40.8% | — | 117 |
| UTMD | $233M | 21.1× | 12.1× | 6.0× | -5.8% | 57.1% | 29.3% | 9.5% | 9.5% | -7.0× | 109 |
| PROF | $208M | 4.0× | — | 12.9× | 50.7% | 70.8% | -264% | -64.1% | -60.0% | — | 59 |
| PDEX | $201M | 15.2× | 14.6× | 2.6× | 16.5% | 31.4% | 17.6% | 28.7% | 21.0% | 0.7× | 68 |
| STIM | $165M | — | — | 1.1× | 99.2% | 48.5% | -26.1% | -174% | -44.2% | — | 87 |
| KRMD | $138M | — | — | 3.4× | 22.2% | 62.3% | -6.4% | -15.5% | -15.5% | — | 84 |
| APYX | $107M | — | — | 2.0× | 9.9% | 62.5% | -21.2% | -77.1% | -22.7% | — | 65 |
| BDMD | $25M | — | — | 1.1× | -39.2% | 83.8% | -121% | -87.0% | -68.0% | — | 10 |
Peers = companies sharing BDMD's sector (Surgical & Medical Instruments & Apparatus) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
No trend data available for this metric.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$1.4M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 4 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -68%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 4 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~8.5% on $8.7M of debt.
Cash of $178K is below short-term debt of $2.6M — relies on refinancing/operations.
Mostly long-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
Top 10 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-10-08
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $22.5M 100.0% | $37.0M 100.0% | $31.5M 100.0% | $35.1M 100.0% |
| Cost of Revenue | $3.7M 16.2% | $4.4M 11.8% | $4.2M 13.4% | $7.1M 20.1% |
| Gross Profit | $18.9M 83.8% | $32.7M 88.2% | $27.2M 86.6% | $28.0M 79.9% |
| Research & Development | $20.1M 89.3% | $6.2M 16.7% | $4.3M 13.6% | $3.9M 11.0% |
| Selling, General & Admin | $14.1M 62.6% | $7.1M 19.2% | $8.5M 27.2% | $7.0M 19.8% |
| Total Operating Expenses | $44.5M 197.5% | $17.3M 46.8% | $15.4M 48.9% | $14.4M 41.1% |
| Operating Income | -$25.6M -113.7% | $15.3M 41.4% | $11.9M 37.7% | $13.6M 38.8% |
| Interest Expense | $737K 3.3% | $576K 1.6% | $284K 0.9% | $299K 0.9% |
| Interest & Investment Income | — | $393 0.0% | $2K 0.0% | $9K 0.0% |
| Other Income (Expense), net | -$100K -0.4% | -$652K -1.8% | -$10K -0.0% | -$195K -0.6% |
| Pretax Income | -$26.4M -117.0% | $14.1M 38.0% | $12.4M 39.3% | $14.5M 41.4% |
| Income Tax Expense | $1.2M 5.2% | $1.5M 4.0% | $1.7M 5.4% | $1.7M 5.0% |
| Net Income | -$27.3M -121.0% | $12.5M 33.6% | $10.5M 33.5% | $12.8M 36.4% |
| Per Share | ||||
| EPS (Basic) | -$0.98 | $0.57 | $0.51 | $0.49 |
| EPS (Diluted) | -$0.98 | $0.57 | $0.51 | $0.49 |
| Weighted Avg Shares (Basic) | 27.8M | 21.8M | 20.6M | 25.6M |
| Weighted Avg Shares (Diluted) | 27.8M | 21.8M | 20.6M | 25.6M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow on any basis, so a reverse DCF can't be run.
EOD close · as of 2026-10-08
Where each multiple sits in its own 4-yr range · 0th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 4-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
ROE -87% against ROIC -68% — -19% of the return on equity comes from leverage and buybacks rather than from the operating business.
Equity is the year-end figure. On average equity over the two year-ends, ROE is -76.8% — the two diverge when buybacks or issuance move equity during the year.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 6.8× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cost of Revenue | 20.1 | 13.4 | 11.8 | 16.2 |
| Gross Profit | 79.9 | 86.6 | 88.2 | 83.8 |
| R&D | 11.0 | 13.6 | 16.7 | 89.3 |
| SG&A | 19.8 | 27.2 | 19.2 | 62.6 |
| Operating Income | 38.8 | 37.7 | 41.4 | -113.7 |
| Income Tax | 5.0 | 5.4 | 4.0 | 5.2 |
| Net Income | 36.4 | 33.5 | 33.6 | -121.0 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on BDMD: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
Earns -66.01pts against its cost of capital — capital is being consumed, not created.
| Period | ROIC | Cost of capital | Spread |
|---|---|---|---|
| FY2022 | 46.5% | 10.0% (today's — no rate published for this year) | 36.4pts |
| FY2023 | 27.3% | 7.4% | 19.9pts |
| FY2024 | 31.9% | 8.3% | 23.7pts |
| FY2025 | -56.0% | 9.1% | -65.0pts |
| Now | -68.0% | 10.0% | -78.1pts |
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2022 | 79.9% | 38.8% | 36.4% |
| FY2023 | 86.6% | 37.7% | 33.5% |
| FY2024 | 88.2% | 41.4% | 33.6% |
| FY2025 | 83.8% | -113.7% | -121.0% |
Return on equity is 19 points BELOW the return on invested capital, which means the equity base is carrying capital the operations are not earning on — usually cash, goodwill, or a recent raise.
ROE is on average equity; ROIC is NOPAT over average invested capital (debt plus equity less excess cash). The gap is not a single adjustment.
$60,303 of goodwill — 0% of invested capital. The gap is what was paid above the fair value of what was bought; it is real capital shareholders provided, so neither bar is the whole answer.
ROIC ex-goodwill is -56.07% against -55.98% reported — the return is earned on a capital base inflated by what was paid for acquisitions, not by the operating business alone.
Free cash flow has fallen short of reported profit in 3 of the last three years.
Reported free cash flow is -$1M; after share-based compensation it is -$19M. The difference is a real cost that the cash flow statement adds back.
Debt is present but there is no positive EBITDA or no reported interest expense, so coverage cannot be measured.
Balance sheet at 2025-12-31. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
No material counter-signal in the checked set: net debt / EBITDA, interest coverage, stressed coverage, maturity schedule vs cash and one year of FCF, liquidity ratios.
Missing from our data, so excluded from this answer: ebitda.
No positive free cash flow to discount, so the price cannot be expressed as a growth requirement.
No material counter-signal in the checked set: reverse-DCF implied growth, historical FCF CAGR, per-year FCF growth distribution, reporting-basis breaks, discount rate used, free-cash-flow basis (stock comp charged?).
Missing from our data, so excluded from this answer: free_cash_flow.
| Step | Amount | Running total |
|---|---|---|
| Net income | −$27M | −$27M |
| Share-based comp | $17M | −$10M |
| Other non-cash & working capital | $8M | −$1M |
| Operating cash flow | −$1M | −$1M |
| Capex | −$42,315 | −$1M |
| Free cash flow | −$1M | −$1M |
| FCF after SBC | −$19M | −$19M |
| Fiscal year | Revenue growth | Receivables growth | Gap |
|---|---|---|---|
| FY2023 | -10.3% | not reported | not reported |
| FY2024 | 17.7% | 49.8% | 32.0 points |
| FY2025 | -39.1% | -8.7% | 30.5 points |
| Fiscal year | DSO | DIO | DPO | Cash conversion cycle |
|---|---|---|---|---|
| FY2022 | not reported | not reported | not reported | not reported |
| FY2023 | 360.8 days | 98.7 days | 47.5 days | 412 days |
| FY2024 | 459 days | 108 days | 104.3 days | 462.7 days |
| FY2025 | 688.8 days | 108.5 days | 180.3 days | 616.9 days |
| Fiscal year | Accruals / assets |
|---|---|
| FY2022 | not reported |
| FY2023 | 20.4 percent |
| FY2024 | 24.1 percent |
| FY2025 | -37.2 percent |
SBC is added back inside operating cash flow, so reported free cash flow treats shares issued to employees as free. Percent of revenue says how expensive the payroll is; percent of operating cash flow says how much of the cash exists only because the charge was added back. The buyback offset is buybacks over SBC — below 1.0 the repurchase does not cover the shares issued.
Figures are the latest fiscal year (FY2025) from the company's own filings, not a trailing-twelve-month window — Q2 reads fiscal years throughout so the cash-conversion ratios and these share one basis. A blank is a line the filer did not report; it is never read as zero.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.